The article by Fintak et al on the incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab.
El-Ashry
Mohamed F
MF
Dhillon
Bal
B
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D009877:Endophthalmitis / Q000453:epidemiology* / Q000382:microbiology; D015818:Eye Infections, Bacterial / Q000453:epidemiology* / Q000382:microbiology; D006801:Humans; D015994:Incidence; D007267:Injections; D000069579:Ranibizumab; D013203:Staphylococcal Infections / Q000453:epidemiology* / Q000382:microbiology; D013212:Staphylococcus epidermidis / Q000302:isolation & purification; D013290:Streptococcal Infections / Q000453:epidemiology* / Q000382:microbiology; D034361:Streptococcus mitis / Q000302:isolation & purification; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D034363:Viridans Streptococci / Q000302:isolation & purification; D014822:Vitreous Body / Q000382:microbiology
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab